BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
 announced by Shareholders Foundation - EconoTimes)
SAN DIEGO, Nov. 16, 2016 -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Michigan on behalf of certain purchasers of shares of Diplomat Pharmacy Inc (NYSE:DPLO) over alleged Securities Laws Violations by Diplomat Pharmacy. The lawsuit seeks to recover damages for certain NYSE:DPLO investors.
Investors who purchased shares of Diplomat Pharmacy Inc (NYSE: DPLO) have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff alleges that the defendants made false and/or misleading statements and/or failed to disclose that Diplomat Pharmacy Inc lacked adequate internal controls over its financial reporting, that as a result Diplomat Pharmacy Inc could not adequately calculate DIR fees, that the Company’s hepatitis C segment was not performing as previously disclosed to investors, that and therefore, Diplomat Pharmacy Inc had overstated its full-year 2016 guidance, and that, as a result of the foregoing, defendants’ statements about Diplomat Pharmacy Inc’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
On November 2, 2016, Diplomat Pharmacy Inc reported third quarter 2016 results. Diplomat Pharmacy Inc also lowered full year 2016 guidance, with the CEO and Chairman commenting, “We are disappointed with our third quarter results, which were significantly impacted by the softness in the hepatitis C business nationwide, as well as by DIR fees. The methodology and transparency around how PBMs are applying these DIR fees changed materially in 2016, and while we cannot reverse the impact they had on this quarter, we are working with our partners in the specialty pharmacy industry and with legislators to achieve an amicable solution to this problem.”
Shares of Diplomat Pharmacy Inc (NYSE: DPLO) declined to as low as $12.47 per share on November 4, 2016.
Those who purchased Diplomat Pharmacy Inc (NYSE: DPLO) shares should contact the Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108
